RLD2002

DRUG2 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

HealthyHypertension

Phase 1

A Study to Evaluate the PK, Safety and Tolerability of HCP1803.

CompletedNCT05723549

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2023-02-02End: 2023-03-20Updated: 2023-09-22

Phase 3

A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

CompletedNCT05362110

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2022-05-16End: 2023-06-05Updated: 2023-09-26

Related Papers

SINGLE-PILL COMBINATION OF THIRD-DOSE TRIPLE ANTIHYPERTENSIVE THERAPY VERSUS STANDARD-DOSE MONOTHERAPY IN PATIENTS WITH MILD TO MODERATE HYPERTENSION

Journal of Hypertension2024-05-011 citations